Argenica Therapeutics company info

What does Argenica Therapeutics do?
Argenica Therapeutics (ASX:AGN) is a clinical-stage biopharmaceutical company pioneering neuroprotective therapeutics to mitigate brain damage after stroke and other ischemic brain injuries. Their lead candidate, ARG-007, is a synthetic peptide designed to target and modulate key cellular pathways triggered by oxygen deprivation, thereby preserving neuronal viability and limiting tissue loss. ARG-007 has demonstrated potential in preclinical models to reduce infarct size, improve neurological function, and enhance post-stroke recovery. Currently in Phase 2 clinical trials, Argenica aims to translate this therapeutic promise into improved outcomes for stroke patients, a critical unmet medical need affecting millions worldwide.
Argenica Therapeutics company media
Company Snapshot

Is Argenica Therapeutics a public or private company?

key
Ownership
Public

How many people does Argenica Therapeutics employ?

people
Employees
8

What sector is Argenica Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Argenica Therapeutics?

location pin
Head Office
Perth, Australia

What year was Argenica Therapeutics founded?

founded flag
Year Founded
2019
What does Argenica Therapeutics specialise in?
/Pharmaceutical /Therapeutics /Biotech /Health /Medicine

What are the products and/or services of Argenica Therapeutics?

Overview of Argenica Therapeutics offerings
Tackling Stroke: developing novel neuroprotective therapies to minimise brain damage after stroke, a leading cause of disability and mortality globally.
Promising Lead Candidate: ARG-007, a synthetic peptide, targets key cellular pathways triggered by oxygen deprivation, aiming to preserve neurons and limit tissue loss.
Preclinical Success: ARG-007 demonstrated efficacy in preclinical models, reducing infarct size, improving neurological function, and enhancing post-stroke recovery.
Phase 2 Clinical Trials: currently investigating ARG-007's safety and efficacy in human patients with acute ischemic stroke, a crucial step towards market approval.
Beyond Stroke: exploring the potential of ARG-007 to treat other ischemic brain injuries, such as traumatic brain injury and hypoxic-ischemic encephalopathy in newborns.
Committed to Innovation: actively researching and developing next-generation neuroprotective therapies to further improve patient outcomes and revolutionize stroke treatment.

Who is in the executive team of Argenica Therapeutics?

Argenica Therapeutics leadership team
  • Dr. Liz  Dallimore B.Sc., M.B.A., Ph.D.
    Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.
    CEO, MD & Director
  • Ms. Emma  Waldon
    Ms. Emma Waldon
    CFO & Company Secretary
  • Prof. Bruno Philip Meloni
    Prof. Bruno Philip Meloni
    Chief Scientific Officer